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Human bloods have been shown to vary in the efficiency with which they. 
0Psonize Group A streptococci in the presence of constant amounts of antibody 
to homologous type M  protein (1, 2). This variation has been found to be due 
to either qualitative or quantitative differences in the accessory plasma factors 
that enhance phagocytosis of antibody-coated organisms. 
The hyaluronic acid capsule of the Group A  streptococcus has been impli- 
cated as an important factor in its resistance to phagocytosis (3--6). Recently, 
Hirsch and Church (7) have postulated that a  "capsule-neutralizing" thermo- 
labfle factor in human plasma is required for the efficient phagocytosis of en- 
capsulated strains. 
This study will present evidence to support the concept that the capsule of 
the Group A streptococcus imposes an opsonic requirement for a  thermolabile 
plasma factor(s)  which is present in varying amounts  in human  bloods and 
which appears to be independent of the complement system. On the assumption 
that this is a plasma cofactor which further enhances the rate of phagocytosis 
of encapsulated organisms in the presence of antibody to M protein and possibly 
complement  components,  it  will  be  referred  to  hereafter  as  streptococcal 
C~coopsonirl.  ~' 
Materials and Methods 
Strains of Streptococci.--Strains of streptococci were selected for use in the bactericidal 
test on the basis of their capacity to resist phagocytosis  and to grow rapidly in human bloods 
in the absence of homologous  type antibody. Most of these strains were freshly isolated from 
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throat  cultures of patients  at  Children's Memorial Hospital,  the Naval Medical Research 
Unit Number  4,  and  the  Northwestern  University Clinics.  Some additional  strains  were 
supplied to us by Dr. Rebecca Lancefield, The Rockefeller Institute, New York; Dr. Elaine 
Updyke,  the Communicable  Disease Center,  Chamblee,  Georgia; Dr.  Armine Wilson,  the 
du Pont Institute,  Wilmington; and  Dr.  W.  Barry Wood, Johns Hopkins Medical School, 
Baltimore. The strains of pnetunococci employed were supplied by Dr. Colin M. MacLeod, 
New York University, New York. 
To maintain strains in a phase of maximal resistance to phagocytosis, it was convenient 
to select those which were mouse-virulent so that they could be passed through mice whenever 
stock cultures showed signs of dissociating.  Capsules were demonstrated  by the wet India 
ink method as described by Wilson (8).  In addition, highly encapsulated  variants were se- 
lected by their tendency to form very short chains in 3 hour cultures in 20 per cent serum- 
broth  (9).  Semiquantitative estimates of M  protein  content  of streptococcal strains  were 
made by preparing hot acid extracts (10) of the sediments of 40 ml of 18 hour Todd-Hewitt 
broth cultures which had been adjusted to a turbidity reading of 100 on a Klett-Summerson 
colorimeter. Serial dilutions of the M protein extracts in 0.85 per cent sodium chloride solu- 
tions  were tested  for  precipitation  against  standard  lots  of homologous,  absorbed,  type- 
specific rabbit antiserum in capillary precipitin tubes.  Strains considered rich in M  protein 
yielded extracts which, under  these conditions, produced  visible M-anti-M precipitates at 
M-extract dilutions of at least 1:40. 
Variant strains of Group A streptococci were selected according to the presence or absence 
of M  protein and hyaluronic acid capsules.  Thus, four groups of variants were studied: M- 
positive,  capsule-positive;  M-negative,  capsule-positive; M-positive capsule  negative,  and 
M-negative, capsule negative. The first category is referred to hereafter as "virulent"  strains 
and the last as "avirulent." 
Studies  of Phagocytosis by Bactericidal Tests.--The bactericidal test employed was identical 
with that described in detail in previous studies (2). Fresh, lightly heparinized human blood 
was mixed with varying dilutions of a culture of Group A streptococci and with homologous 
type antiserum.  The survival of organisms was determined by colony counts of pour plates 
made from the mixtures after 3 hours of incubation in a  roller tube apparatus  at 37°C.  To 
demonstrate a strongly positive bactericidal effect, phagocytosis had to be rapid and efficient, 
otherwise the population of extracellular streptococci increased faster than  it could be re- 
duced by blood phagocytes. The system was, therefore, very sensitive to factors influencing 
the rate of phagocytosis. In the absence of thermolabile plasma factors,  no significant bac- 
tericidal  effect was  detected against  virulent  streptococci despite the presence of optimal 
amounts of homologous antiserum (2). The method was, therefore, very effective for detecting 
variations in accessory plasma  factors involved in opsonization. 
For convenience, the results of the bactericidal tests were expressed  as an index based 
upon the relative growth of streptococci in blood containing optimal amounts of homologous 
antibody  compared  with control  samples  in which type-specilic antibody was absent  (2). 
For example, a bactericidal index of 100 indicated that growth of the inoculum was 100 times 
greater in the control tubes than in the tubes containing homologous type antibody. Human 
bloods were compared for relative opsonic strength  by determining their bactericidal effect 
in the presence of an excess of homologous type antiserum. Strongly positive tests were those 
with indices of 500 or greater. An index of 25 was considered the lower limit of significant 
opsonic activity. An index of i indicated uninhibited growth of the inoculum. 
In experiments involving opsonization of avirulent  strains  of Group  A  streptococci, all 
human bloods studied showed a marked phagocytic effect which was only slightly enhanced 
by supplementing the system with rabbit antiserum prepared against these strains. The bac- 
tericidai index in such cases was derived by comparing growth of avirulent strains in cell-free G.  H.  STOLLERMAN~ M.  RYTEL~ AND  J.  ORTIZ  3 
plasma with that in whole blood of the same donor. A slight modification of the bactericidal 
test was  also  necessary in studies of phagocytosis of pneumococci.  Because of the slower 
growth of these organisms compared with streptococci, the period of the test was extended 
from 3 to 6 hours and the inocula were increased at least tenfold. 
In view of the large number of variables inherent in the bactericidal test,  experiments 
were designed so that, as often as possible, only one variable was tested in the same experi- 
ment.  For example,  a  variety of strains with different properties were tested in the same 
experiment with the blood of a  single individual, and, conversely, a  single strain was tested 
in another experiment with the bloods of various individuals. 
Experiments  involving various  modifications  of  plasma  factors  were  made  as  follows: 
Freshly drawn heparinized bloods were centrifuged at 4°C and the supernatant plasma was 
separated  from the cells.  The sedimented blood ceils were washed twice in  10  volumes of 
cold Tyrode-gelatin buffer and were reconstituted with equal parts of aliquots of the original 
plasma modified according to the experimental plan. White blood cell counts were made on 
the reconstituted mixtures and adjusted, when necessary, to the concentration of the original 
whole blood sample. No attempt was made to separate red from white blood cells, and indeed, 
an effort was made to vary conditions as little as possible from that of whole blood. By this 
method,  the  washed  blood  cells  resuspended  in  fresh  plasma  produced  bactericidal  tests 
which were consistently as strong as those of whole blood. 
Direct Opsonopkagocytiv Tests.--In  some  experiments,  the rate of phogocytosis was  ob- 
served microscopically by conventional direct opsonophagocytic counts. At frequent intervals 
during the 3 hour period of incubation of the bactericidal test, a drop of the test mixture was 
removed, spread on a glass slide and stained with Wright's stain. The conditions were identical 
to those of the bactericidal test except that the concentration of organisms in the culture was 
increased by about  1000 times to insure adequate numbers of phagocytized streptococci to 
count. 100 polymorphonuclear leucocytes were counted on each of 2 slides prepared from the 
contents of the same test tube.  Phagocytosis was expressed as the percentage of polymor- 
phonuclear leucocytes counted that contained streptococci (phagocytic index). 
Complement Components.--Complement  was  measured  quantitatively  as  described  by 
Kabat  and  Mayer  (11).  Complement  components were  assayed  by  the  reagent  titration 
method  described by Wedgwood  (12).  Properdin was  assayed  by the zymosan method of 
Pillemer and associates (13). 
Bentonite Absorption Tests.--Wyoming bentonite, ly.s.P,  was prepared as a  suspension of 
uniform particle size according to the method of Bloch and Bunim (14).  Stock suspensions 
containing approximately 0.5 mg of bentonite per ml of water were employed and the well 
drained sediment of 0.3 to 3.0 mg of bentonite particles was resuspended in 1 ml aliquots of 
fresh plasma for 20 minutes at 37°C. The particles were removed by centrifugafion in the cold 
at 15,000  X  G/or 30 minutes. Washed blood cells were then resuspended in equal volumes of 
the supernatant,  bentonite-absorbed plasma and bactericidal tests were made as described 
above. 
Absorption of Plasma  Opsonina with  Strains  of Group A  Streptococci.--18 hour  Todd- 
ttewitt broth cultures of the variant strains of Group A streptococci studied were centrifuged 
and the sedimented cells resuspended in fresh Todd-Hewitt broth and adjusted to a turbidity 
reading of 100 on a Klett-Summerson colorimeter. Colony counts made from such standardized 
cultures averaged approximately 2 X  108 per ml. Sedimented cells from volumes ranging from 
1 to 3 ml of these cultures were washed twice in 5 ml volumes of 0.85 per cent sodium chloride, 
resedimented, drained and suspended in fresh plasma. After incubation at varying tempera- 
tures for 20 minutes with frequent agitation of the tubes, the plasma-bacterial suspensions 
were centrifuged at approximately 15,000  X  G for 30 minutes at 0°C and the supernatant 
plasma pressed through a  Millipore filter (0.65#). The filtered plasma was then employed as OPSONIC FACTOR FOR  ENCAPSULATED  STREPTOCOCCI 
a suspending medium for equal volumes of washed blood cells. Bactericidal tests were made 
with these reconstituted bloods against virulent strains of Group A streptococci  in the pres- 
ence of homologous  type, heat-inactivated rabbit antiserum, as described above. 
RESULTS 
Specificity of the  Opsonic  Deficiency  of Some  Human  Plasmas for  Virulent 
Group A  Streptococci.--In most of the studies to be reported, the bloods of two 
individuals  (GHS and CL) were selected. These were found to be most strik- 
ingly deficient in opsonie activity against virulent  Group A  streptococci (2). 
TABLE I 
Bactericidal Tests Made With Human Bloods of  Varying Streptococcal Coopsonin Content 
Donor  Organism  Bactericidal  Index~ 
GHS* 
CL* 
MR 
KK 
GHS* 
CL* 
MR 
KK 
GHS* 
CL* 
MR 
KK 
Type 3 virulent streptococci 
,c  ~C 
g~  gt 
Type 3 pneumococci 
,,  I~C 
gg  ¢~ 
,l  gg 
Avirulent streptococci (T2/44/19) 
gg  l~ 
51 
64 
8,578 
6,336 
54,656 
26,400 
34,304 
29,504 
5,232 
1,246 
800 
17,472 
* Deficient bloods. 
:~ (See Methods) Bactericidal index is an expression for inhibition of growth of streptococci 
in presence of homologous  antibody compared with growth in control bloods in the absence 
of antibody. Anindex of 25 to 100 =  1 +; 100 to200 =  2+; 200 to500 =  3+; and greater 
than 500 is 4+ inhibition of growth. 
These bloods will be referred to hereafter as "deficient" in contrast to the more 
usual behavior of most human bloods, referred to hereafter as "normal" (MR 
and  KK in  Table  I).  The  deficient bloods produced weak bactericidal  tests 
consistently during several years of observation against all typable, encapsu- 
lated strains of Group A streptococci tested. This deficiency could not be demon- 
strated, however, in any other phagocytic system studied. Avirulent Group A 
streptococci,  containing neither  demonstrable  M  protein  nor  capsules,  were 
phagocytized and  destroyed  with  equal  efficiency by  normal  and  deficient 
bloods.  Similarly, virulent Type III pneumococci were destroyed equally well 
in the presence of homologous type antiserum by both kinds of blood (Table I). 
The rate of phagocytosis by normal and deficient bloods also was determined 
by timed experiments  in which blood smears were made at regular intervals G.  H.  STOLLERMAN,  M'.  RYTEL,  AND  3.  ORTIZ 
during the incubation period of the bactericidal test and the degree of phago- 
cytosis  was  measured  by  direct  opsonophagocytic  counts  (see  Methods). 
Phagocytosis of virulent Group A streptococci was slower in the deficient bloods 
than in the normal bloods. This difference in the behavior of the two types of 
bloods was not apparent,  however, when timed phagocytic tests were made 
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FIO. 1. Slow  rate of phagocytosls  of Group A streptococci by human bloods deficient  in a 
coopsonin apparently not required for rapid phagocytosis  of other agents studied. Phagocytic 
index refers to percentage of polymorphonuclear  lencocytes  counted which contain bacteria 
or particles (see Methods). 
with  avirulent  Group  A  streptococci,  virulent  Type  HI  pneumococci,  or 
zymosan granules (Fig. 1). 
Tke  Relationskip  between Encapsulation  of Group A  Streptococci and  tke 
Phagocytic Requirement for a Plasma Coopsonin.--Variant  strains of Group A 
streptococci  were  selected  for  bactericidal  tests  with  normal  and  deficient 
bloods. The variants included encapsulated and non-encapsulated organisms. 
These were further subdivided into strains which did, and strains which did 
not, contain M protein. 
In the absence of homologous type antibody, encapsulated strains rich in M OPSONIC FACTOR  FOR ENCAPSULATED  STREI~TOCOCCI 
protein resisted phagocytosis and grew at optimal rates in all bloods studied. 
In the presence of homologous type antibody, all such strains were phagocytized 
efficiently by normal bloods (strongly positive bactericidal tests) and relatively 
inefficiently  by deficient  bloods (weakly positive bactericidal tests).  Variants 
which possessed large  capsules,  but which did not contain  M  protein,  were 
phagocytized to some extent by normal bloods, even in the absence of homolo- 
gous type antibody. These strains were phagocytized much less efficiently by 
the deficient bloods, with or without the addition of homologous antiserum. 
Conversely, unencapsulated  strains,  with or without M  protein in  their  cell 
walls,  were phagocytized equally well by normal  and  deficient bloods, with 
and without the addition of homologous rabbit antiserum to the system (Table 
TABLE  II 
Rdationship of Encapsulation  of Streptococcal Strains to the Requirement for a Streptococcal 
Co~ ,sonin in Human Plasma 
Source of blood 
Normal 
Deficient 
Normal 
Deficient 
Homologous 
antiserum 
None 
None 
Present 
Present 
Bactericidal indices against streptococcal variants 
Encapsulated  Non-encapsulated 
M+  M-- 
1  18 
1  2 
768  51 
83  3 
M+  M- 
19  358 
18  437 
1056  4074 
912  3056 
II).  On the basis of these observations, it appeared that  the presence of the 
streptococcal capsule imposed a requirement for a plasma opsonin which was 
not present to the same extent in all human bloods. 
The Relative Requirement for  Thermolabile Opsonin in  the  _Phagocytosis of 
Encapsulated and Unencapsulated Streptococcal Strains.--The following experi- 
ments were made to determine the relative importance of thermolabile opsonins 
in the phagocytosis of various strains of Group A streptococci: 
Washed blood cells were resuspended in equal volumes of fresh, normal human plasma 
which had been diluted progressively with the heated plasma (56°C for 30 minutes) of the 
same individual. Phagocytosis was studied by bactericidal tests made in the presence of a 
constant amount of antiserum to the homologous type of streptococcus. 
A higher concentration of fresh plasma was required for optimal phagocytosis 
of encapsulated strains than that which was required to promote the phagocyto- 
sis  of unencapsulated  strains.  For  example,  a  40  to  60 per cent dilution  of 
fresh plasma  in  heated  plasma  resulted  in  almost complete loss  of the bac- 
tericidal effect of the system against encapsulated strains, whereas comparable G. H. STOLLERMAN~  M. RYTEL~ AND J. ORTIZ 
dilutions of thermolabile factor(s) had less effect upon the rate of phagocytosis 
of unencapsulated  strains  (Table  III). 
Deficiency of Coopsonin in Human Bloods which Contained Normal Amounts 
of Complement.--The following experiments suggested that rapid phagocytosis 
of  encapsulated  streptococci  required  certain  plasma  opsonins,  (other  than 
complement), which were decreased or absent in some human bloods. 
Fresh plasma from a normal individual, MR, was diluted in increasing amounts of heated 
plasma from the same individual, as in the preceding experiment. The fresh plasma of MR 
TABLE III 
Recuirement for Tkermolabile Plasma Factors in the Phagocytosis of Encapsulated and 
Non-Encapsulated Streptococci 
Fresh plasma* 
~er ~ent 
100 
80 
60 
4O 
20 
0 
Bactericidal indices against streptococcal variants$ 
M+ 
460 
105 
55 
7 
1 
1 
Encapsulated 
M-- 
22 
7 
6 
1 
1 
1 
M+ 
2624 
896 
768 
371 
352 
16 
Non-encapsulated 
M- 
3840 
3328 
704 
51 
26 
13 
* Fresh plasma diluted in the heated plasma of the same individual. 
Autologous washed blood cells were resuspended in plasma mixtures and bactericidal 
tests were made against streptococcal variants in the presence of inactivated homologous 
type rabbit antiserum. 
was similarly diluted in thefresk, unheated plasma of GHS, a deficient donor. Washed blood 
cells of MR were then resuspended in these mixtures and bactericidal tests were made against 
highly encapsulated, M protein-rich strains of Group A streptococci  in the presence of homolo- 
gous type antiserum. 
A representative experiment is shown in Table IV. Phagocytic activity de- 
creased progressively when normal plasma was diluted in either heated, normal 
or in unheated,  deficient plasma. 
The  Relationship  of the Complement System  to  the  Phagocytosis-Promoling 
Factor for  Encapsulated  Streptococci.--The  opsonic  deficiency  in  the  fresh 
plasma of the human bloods studied could not be accounted for by a decrease 
in any of the 4 conventional components of complement, or of properdin. The 
sera of GHS and  CL contained normal titers  of C'I, Ct2,  C'3 and  C'4, and 
contained  between 6  and  10  units  of properdin,  measured  by the  zymosan 
assay.  These deficient plasmas also contained normal virucidal titers  against 8  OPSONIC  ]FACTOR  FOR  ENCAPSULATED  STREPTOCOCCI 
Escherichia  coli  bacteriophage  T2  r+,  normal  bactericidal  activity  against 
Salmonella typhi, Shigella sonnei, 1 and E.  coli, and normal levels of lysozyme. 
Blood platelets did not appear to play any significant role in the opsonization 
of virulent streptococci. Bactericidal  tests were no different with platelet-rich 
compared with platelet-poor preparations  of plasma prepared from the bloods 
of either normal or deficient individuals. 
Removal of any one of the individual components of the complement system 
from normal sera  (preparation  of complement reagents  R1,  R2,  R3, and R4) 
resulted  in  marked  decrease  in  the  bactericidal  tests  against  encapsulated 
TABLE IV 
Demonstration of Deficiency in Streptococcal Coopsonin in Human Plasma (GHS) Containing 
Normal A mounts of Complement 
Plasma  mixture 
MR  fresh  MR heated 
plasma  +  plasma 
ml  ral 
1.0 
0.8  0.2 
0.6  0.4 
0.4  0.6 
1.0 
Bactericidal index 
T5* 
2000 
2000 
134 
33 
1 
Plasma mixture 
MR fresh  GHS  fresh 
plasma  +  plasma 
ml  ml 
1.0 
0.8  0.2 
0.6  0.4 
0.4  0.6 
--  1.0 
Bactericidal 
Index T5* 
2000 
1904 
525 
105 
42 
* Washed blood cells of MR were resuspeaded in plasma mixtures and bactericidal tests 
were made against  virulent Type 5 streptococci in the presence of homologous rabbit anti- 
serum, 
streptococci.  It appeared,  therefore,  that  complement  either  participated  in 
the  opsonization  of these  organisms  or  that  the  manipulations  of the  serum 
required  to prepare  these  fractions destroyed some other very labile  opsonin 
present in low fiter. 
Absorption  of Streptococcal Coopsonin  by Bentonlte.--Becanse  bentonite  has 
been employed as an absorbent of a variety of serum factors (15-17) and does 
not, under certain conditions, absorb complement (18), it was employed in the 
following  experiments  in  an  attempt  to  selectively  absorb  streptococcal 
coopsonin. 
Fresh plasma from normal bloods was absorbed with varying amounts of bentonite, ranging 
from 0.3 to 3.0 mg per ml of plasma, for 15 to 20 minutes at 37°C. The bentonite  particles 
were removed by centrifugation  at 15,000 X  G for 30 minutes at 4°C. Washed blood cells 
were resuspended in equal volumes of bentonite-absorbed  plasmas and the mixtures tested 
1  The bactericidal assays of deficient plasmas against  E. coli bacteriophage, S. typhi and 
Sh.  sonnei were kindly  made by Dr.  Ralph E.  Wedgwood, Western  Reserve  University. 
Titers of complement components and of properdin  also were confirmed by his laboratory. G.  H.  STOLLERMAN~ M'.  RYTEL~ AND  J.  ORTIZ 
for bactericidal activity against various strains of Group A  streptococci in the presence of 
homologous rabbit antisera. 
Absorption  of plasma  with  bentonite  resulted  in  marked  decrease in  co- 
opsonin  without  loss  of  complement.  The  decrease  in  coopsonin was  most 
apparent in bactericidal tests made with strains of Group A streptococci which 
possessed the largest capsules.  Absorption of plasma with larger amounts of 
bentonite was required to reduce the opsonization of strains which possessed 
smaller capsules.  Finally, opsonization of unencapsulated, M-negative strains 
was least affected by bentonite absorption of plasma (Table V). 
The loss of opsonic activity of bentonite-absorbed plasmas was not associated 
TABLE V 
Effect of Absorption of Plasma Witlt Bentonite Upon Cofactors Involved in the Opsonization of 
Virulent and Avirulent Group A Streptococci 
Bentonite per ml plasma 
mg 
o 
0.3 
0.6 
C' 
u/mt 
38 
37 
38 
Activity of plasma in bactericidal test against:* 
Virulent streptococci~ 
(T3/34~S) 
563 
83 
13 
Avirulent streptococci§ 
1700 
1134 
340 
* Washed blood cells were resuspended in the absorbed plasmas and  bactericidal tests 
were made in the presence of heated homologous rabbit antiserum. 
Encapsulated, M  protein-rich, mouse-virulent strain. 
§ Non-encapsuLated, M-negative, mouse-avirulent strain. 
with significant  decrease in  total  complement activity.  Nevertheless,  it was 
considered possible that there might have been a reduction in some component 
of complement that would not be detected by the hemolytic assay for whole 
complement. All four components of complement and properdin were assayed, 
therefore, before and after absorption of a normal plasma with bentonite (1 mg 
per ml of plasma). Bactericidal tests were then made against each of two en- 
capsulated strains  of M-rich streptococci by resuspending washed blood cells 
in the absorbed plasmas. A marked decrease in opsonic activity of the plasmas 
occurred  following  bentonite  absorption  in  the  absence  of  any  significant 
change in the titers of the four components of complement,  or of properdin 
(Table VI). 
Attempts to Absorb Streptococcal  Coopsonin on Highly Encapsulated Strepto- 
coccal  Cells.--The  possibility  was  considered  that  streptococcal  coopsonin 
might combine directly with the hyaluronic acid capsule of Group A strepto- 
cocci and might thus be absorbed selectively from plasma by highly encapsu- I0  OPSONIC FACTOR FOP, ENCAPSULATED STREPTOCOCCI 
lated strains. Accordingly, human sera, which were known to be free of antibody 
to the M protein of the homologous type organism, were absorbed with different 
variants  of  Group  A  streptococci and  residual  complement  and  coopsonin 
activity of the plasma were studied. When serum was absorbed at 37°C, com- 
plement activity and coopsonin activity were both markedly reduced by all 
strains except those which were very rich in M  protein, and which possessed 
large capsules.  The latter strains did not reduce components of complement 
significantly when suspended in a concentration of 2 X  1@ to 6 X  108 organisms 
per ml of human serum at 37°C for 20 minutes.  Furthermore, adsorption of 
homologous type M protein to these virulent strains prior to their suspension in 
TABLE VI 
Absorption of Streptococcal Coopsonin  from Plasma b: 
Absorbed with: 
Unabsorbed 
Bentonite (1 
mg/ml) 
, Bentonite 
Complement titers (tt/mI)* 
C____~'  C'___~I C'____~2  C'___~3  C'4 
120  1280  480  960  1920 
120  1920  320  640  1280 
Pro- 
perdin 
u/mt 
6 
6 
Bactericidal index 
TS~:  T6__.__~ 
1~820  320 
1 
* Measurements  of  the  components of  complement  are  expressed  in  the units of  the 
reagent titration technique of Wedgwood (12). 
Washed blood cells  were resuspended in absorbed and unabsorbed plasmas, respectively, 
and bactericidal tests were made against virulent Type 5 and Type 6 streptococci, respec- 
tively, in the presence of homologous  rabbit antiserum. 
normal human serum, or absorption of human serum which contained homolo- 
gous type M protein, did not reduce complement under the above conditions. 
Absorption of serum at 37°C with these virulent strains of streptococci re- 
sulted in some decrease in opsonic activity but this result was not consistent, 
contrary to a preliminary report (1), and varied with individual human sera 
and with the strain employed. Avirulent organisms at this temperature removed 
both complement and opsonic activity. At 0°C, absorption of serum with aviru- 
lent strains in concentrations of 2 to 6 X  108 organisms per ml did not reduce 
complement but, again, reduction of opsonic activity was variable with indi- 
vidual sera and not marked. The addition of purified streptococcal hyaluronate 
in concentration of from 1 to 10 nag per ml did not interfere significantly with 
coopsonin activity. Higher concentrations of hyaluronate (up to 40 mg per ml) 
decreased phagocytosis but these concentrations were also anticomplementary. 
We  were  unable  to  demonstrate  convincingly,  therefore, a  marked  affinity 
between the streptococcal hyaluronate capsule and a serum opsonin. 
Absorption of Coopsonin with Yeast Cell Walls (  Zymosan).--It was considered G.  H.  STOLLERMAN, M.  RYTEL, AND J.  ORTIZ  11 
of interest to determine  the effect of absorption of serum with cell walls of or- 
ganisms  other  than  streptococci  to  which  most  human  sera  contain  either 
specific  or  cross-reacting  "natural"  antibodies.  Sera  were  absorbed  with 
zymosan  at  17°C  to  prepare  a  "properdin-deficient"  (RP)  reagent.  Some 
samples  of  RP  were  reabsorbed  at  37°C  to  prepare  a  "properdin-free" 
(RPb)  reagent,  according  to  the  method  of  Pillemer  and  associates  (13). 
In  addition,  aliquots  of  the  same  individual's  fresh  serum  were  absorbed 
at 0 ° with the same amounts of zymosan (1.5 mg per ml of plasma)  and with 
amounts up to 8 mg of zymosan per ml of plasma. 
TABLE VII 
Effect  of Absorption  With  Zymosan  Upon  the Streptococcal Coopsonin Aaivily  of Normal 
Human Plasma 
Subject  Suspending  medium for washed  Complement  Bactericidal indices against 
blood cells  virulent strep 
LK 
MH 
~C 
PB 
MR 
Whole plasma 
RP* 
Whole plasma 
RPb~ 
Whole plasma 
RPb 
Whole plasma 
Absorbed at 0°C§ 
33 
22 
38 
28 
37 
34 
38 
38 
2500 
90 
908 
6 
457 
2 
640 
582 
* RP, plasma absorbed at 17°C with zymosan (1.5 mg/ml). 
RPb, plasma absorbed at 17°C, and again at 37°C, with zymosan. 
§ Absorption of plasma with amounts of zymosan up to 8 mg per ml at 0°C did not de- 
crease bactericidal index. 
Thrice washed blood ceils were resuspended in aliquots of serum which had been absorbed 
at various temperatures  with zymosan, and in unabsorbed  serum from the same individual 
as a control. The reconstituted  blood cell-plasma mixtures were then inoculated with cultures 
of virulent streptocci, homologous type rabbit  antiserum  was added, and bactericidal tests 
were made. 
Absorption of serum with zymosan at  17°C resulted  in marked loss of bac- 
tericidal activity of the reconstituted  bloods (Table VII). The loss of activity 
was not associated  with  a  comparable  decrease  in complement.  The opsonin 
could not be removed at 0°C by zymosan in amounts  up  to 8  nag per ml of 
plasma.  Under  these  conditions,  complement  was  not  reduced.  The  opsonic 
activity could not be restored by the addition of "purified properdin"  (18)  to 
system3  Streptococcal  coopsonin  was  inactivated,  however,  by  the  addition 
to human plasma of a  rabbit antiserum to human "purified properdin ''2 under 
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conditions which did not reduce complement nor form visible antigen-antibody 
precipitates (19).  From the above experiments, it appeared that the coopsonin 
for  encapsulated streptococci  could be  absorbed  or neutralized by antigen- 
antibody complexes other than those specific for streptococci and that it could 
be  neutralized by antibodies made against  the  fraction of serum known to 
contain so called "properdin". 
Sephedex Gel Filtration of Plasma Opsonins.--Because of the lability and 
small concentration of streptococcal coopsonin, dialysis and various plasma pro- 
tein fractionation procedures  which were  attempted to further characterize 
this factor were found to be unsatisfactory. The molecular sieving effects of 
dextran gels (20)  (Sephedex  a) were found to be useful, however, in obtaining 
serum fractions of varying molecular size which could be tested for coopsonin 
activity. 
Fresh, human serum was filtered through columns of Sephedex saturated with Tyrode's 
buffer. 3 to 5 ml samples of serum were passed through columns 15 cm high and 1 cm in 
diameter at 4°C. Under these conditions, effluent samples were obtained, within 30 to 40 
minutes, which contained concentrations of serum protein and complement titem almost 
equal to those of the original, unfiltered serum. Equal volumes of washed blood cells were 
added to the effluent  samples of gel-filtered  serum proteins  in Tyrode's buffer,  and bactericidal 
tests were made against virulent streptococci. 
Complete opsonic activity of the serum proteins was recovered after filtra- 
tion through G 75 Sephedex in Tyrode's buffer. The molecular weight of strepto- 
coccal coopsonin appeared to be, therefore, greater than approximately 50,000. 
Gel filtration of the deficient plasmas through G 75 Sephedex did not increase 
their opsonic activity. The weak opsonic activity of these plasmas, therefore, 
could not be interpreted as being due to a  plasma inhibitor with  molecular 
weight of less than 50,000. 
DISCUSSION 
The resistance of Group A streptococci to phagocytosis by blood leucocytes 
has been shown to be related to the presence of at least two surface components, 
M  protein and hyaluronic acid capsules  (3-7).  In the absence of these com- 
ponents, Group A  organisms are opsonized by the bloods of all mammalian 
species studied. It is probable, therefore, that the M protein-rich, encapsulated 
Group  A  streptococcus  owes  its  striking  resistance  to  phagocytosis to  the 
elaboration of a surface conta~ing a highly specific, non-cross-reacting antigen 
(M protein) and a non-antigenic polysaccharide chemically identical with that 
of mammalian host tissues (hyaluronic acid). In the absence of antibody to M 
protein, such a surface might not be readUy recognized as "foreign" by blood 
phagocytes. Previous studies by Wiley and Wilson (21)  have shown that  re- 
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sistance to phagocytosis remains unchanged in streptococci killed by methods 
which produce minimal denaturation or alteration of cell surface, and that such 
resistance,  therefore, does not appear to be due to the elaboration by living 
organisms  of any active substance "toxic" to the blood phagocytes. 
In  support  of  the  concept of  relative  "non-reactivity"  of  the  surface  of 
virulent  streptococci with  non-type-specific opsonic antibodies  in plasma  is 
the failure of such organisms  to absorb complement fromhuman sera in contrast 
to the marked complement-absorbing properties of avirulent Group A strepto- 
cocci at 37°C.  Furthermore,  in the presence of homologous M  antibody, ab- 
sorption of complement by virulent organisms  is not  significantly  enhanced. 
It would appear, therefore, that M-anfi-M complexes in the hyaluronic acid gel 
matrix of the streptococcal capsule do not have marked affinity for complement. 
The studies reported here develop further  the line  of investigation which, 
for several years,  has pointed  to an  opsonic factor  in  human  serum which 
results  in  efficient  in  vitro  opsonization  of  virulent  Group  A  streptococci. 
Rothbard's studies first demonstrated  the increased opsonic power of human 
sera, compared with that of other mammals (5). Maxted (22) and Fleck (23) 
confirmed these differences and the former showed that monkeys also possessed 
the plasma opsonin effective against virulent streptococci. Stollerman,  Kantor, 
and Gordon (2) showed individual variation in the quantity of opsonic acces- 
sory plasma factors within human  and  rabbit species.  Subsequently, Hirsch 
and  Church  (7) demonstrated the critical role played by the hyaluronic acid 
capsule of Group A streptococci in determining  a  requirement for particular 
plasma opsonin(s).  The studies presented here further  demonstrate  that  the 
variations of opsonic power of human plasmas are due to relative deficiencies 
of the accessory plasma factor(s) required to opsonize encapsulated streptococci. 
In addition, they show the separate identity of this factor from conventionally 
defined components of the hemolytic complement system. 
The relationship of the streptococcal coopsonin to the complement system is 
not entirely clarified  by the studies reported.  Although  the accessory factor 
does not appear  to be a  complement component,  it cannot be stated as yet 
that  this  opsonin  operates in  the absence of complement.  Manipulations  of 
serum  which  remove or  diminish  any  component  of complement markedly 
affects opsonization, either because the integrity of the complement system is 
required for full opsonic activity of the plasma, or because such manipulations 
also remove or destroy the coopsonin which appears to be present in very low 
titer.  So far,  the coopsonin has not been purified.  Until this is accomplished 
it does not seem possible to determine whether or not coopsonin can act alone 
with the M-anti-M complex to enhance phagocytosis or whether it is a cofactor 
which is required to activate  the complement system. 
With  regard  to  the latter  hypothesis,  there  are several analogies.  Recent 
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enhance  the  hemolysis of sensitized red  blood cells,  or  the  precipitation  of 
aggregated gamma globulin, and which appear  to be separate from, and ac- 
cessory  to,  the  complement  system  (24-26). 
An alternative explanation of the streptococcal coopsonin could be that it is 
a  plasma factor which combines directly with hyaluronic acid and thus neu- 
tralizes, in some as yet unexplained way, the latter's anti-phagocytic effect (7). 
Such an hypothesis would be more attractive if it were possible to specifically 
absorb the coopsonin with encapsulated streptococci or ff the coopsonin were 
readily neutralized by the addition to plasma of streptococcal hyaluronic acid. 
Neither was accomplished convincingly in  this  study. 
The presence of a capsule and M protein on the cell surface, therefore, may 
impose a  very critical requirement for a  maximal concentration of the com- 
ponents of a  more general phagocytosis promoting system, such as that de- 
scribed by Tullis and Surgenor (27). The latter authors demonstrated reduction 
of the opsonic activity of plasma for starch granules by absorption of serum 
with zymosan or with powdered barium sulphate. They, too, were unable to 
reactivate phagocytosis by the addition of purified properdin,  and they con- 
sidered their system to be independent of complement. 
Opsonization of avirulent, non-encapsulated organisms may require a  very 
small amount of such a factor(s), perhaps because of the more reactive nature 
of the antigen-antibody complexes formed with cell wall antigens other than 
M protein. The "deficient" bloods described in this study may have adequate 
amounts of phagocytosis promoting factors for such reactive complexes and 
the deficiency may not become apparent until formation of these antigen-anti- 
body complexes are blocked or"masked" by an excess of M protein and hyalur- 
onic acid at the cell surface. Under the latter conditions, M-anti-M complexes 
might  require  nmch  higher concentrations of  the same  cofactors  to  stimu- 
late phagocytosis. Some support for the latter hypothesis is provided by the 
fact that absorption of sera with sufficient amounts of bentonite eventually 
decreases  opsonization of avirulent, as  well as  of encapsulated, streptococci 
without decreasing complement titers. This reduction in opsonic activity occurs 
even in the presence of excess amounts of heated antiserum to the homologous 
strain of organisms. Thus, bentonite appears  to remove opsonins other than 
complement and specific antibodies which are involved in the phagocytosis of 
avirulent, as well as of encapsulated, streptococci.  The affinity of bentonite 
for alpha and beta lipoproteins (17)  is well known, and absorption of plasma 
with this substance may remove a  group of plasma factors which seem to be 
involved in  the  acceleration of phagocytosis. 
The biological or clinical significance, if any, of the  coopsonin is not yet 
apparent. Preliminary studies of adults with advanced rheumatic heart disease 
do not reveal, so far, any consistent pattern of coopsonin deficiency compared 
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studied have normal plasma coopsonin activity. The remainder show varying 
degrees  of deficiency (28).  Studies of possible variations of coopsonin activity 
during the acute phase of febrile reactions in normal donors are in progress.  In 
one experiment, fever induced artificially with typhoid vaccine did not increase 
streptococcal coopsonin in the blood of one of the deficient  donors (29). 
SUMMARY 
A study was made of the nature of the thermolabile plasma factors in human 
blood which promote the phagocytosis of Group A streptococci in vitro in the 
presence of optimal amounts of type-specific M  antibody. The plasmas of in- 
dividuals with strong opsonic activity (normal)  were compared with those of 
some individuals whose opsonic activity was consistently weak (deficient). 
A general relationship was established between encapsulation of streptococci 
and  the opsonic  requirement for thermolabile plasma factor(s). Marked dif- 
ferences in phagocytosis of Group A organisms  by human bloods were demon- 
strated with encapsulated strains only. Human bloods deficient in the cofactor 
required for opsonization  of encapsulated streptococci (coopsonin)  showed a 
normal rate of phagocytosis against all other organisms  and particles studied. 
Furthermore, coopsonin-deficient  bloods contained normal levels of four com- 
ponents of complement, of properdin,  of lysozyme, and of direct bactericidal 
activity against  several  species  of  Gram-negative  organisms  and  of E.  coli 
bacteriophage. 
The  independence  of  the  streptococcal  coopsonin  from  complement  was 
also demonstrated by absorption of plasma with bentonite and with zymosan. 
Under appropriate conditions,  the coopsonin was reduced without significant 
loss of complement. 
The data support the concept that the capsule of the streptococcus imposes 
an  opsonic requirement  for a  plasma  factor(s)  which  is  present  in  varying 
amounts in human bloods and which appears to be independent of the com- 
plement system. The possibility that it is accessory to the latter components 
has not been excluded. 
The technical assistance of Mary Roberts  is gratefully acknowledged. 
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